Australia's deadliest drug year on record: seven deaths a day in 2024

What just happened

Australia recorded 2,596 drug-induced deaths in 2024 — the highest number on record, equivalent to seven deaths every day. The Penington Institute released these figures on 16 June as the early release of their 2026 Annual Overdose Report, documenting a 10.7% increase from 2023 and the first time unintentional overdose deaths exceeded 2,000 in a single year.

There is a detail in those numbers that deserves sitting with: for the first time in the decade of data collected, people aged 50–59 experienced the most unintentional overdose fatalities. This was not the demographic most media coverage, or most public imagination, would point to as the heart of the overdose crisis. The image most of us carry is younger. The data says otherwise.

If you are in your forties or fifties — if you manage someone who is, or if you have simply assumed that overdose is someone else’s problem — these numbers matter.

---

The both-and

The overdose crisis is real, worsening, and increasingly a story about prescription medicine, polypharmacy, and the physiology of middle age. It is also genuinely complicated to address — because the medications most involved are also medicines that many people legitimately need.

What the numbers actually show

Opioids were involved in 1,083 unintentional overdose deaths. Benzodiazepines were involved in 696. Stimulant-related deaths rose 25.1% in a single year, with cocaine-related deaths up 28.2%. Over 70% of unintentional overdose deaths involved two or more substances simultaneously. Alcohol was present in nearly one in five.

These are not, in the majority, people dying from a single deliberate act with a black-market drug. They are overwhelmingly people who died from combination — prescribed opioids alongside a benzodiazepine alongside a standard evening drink, or a sleep aid added to a pain medication taken for years without incident until the slower clearance of a 55-year-old kidney shifted the margin.

Why the 50–59 age group

The Conversation’s accompanying analysis outlines the convergence of factors that makes this group particularly vulnerable. Kidney and liver function decline with age, slowing how drugs are cleared and extending how long they stay active in the body. Chronic conditions accumulate — chronic pain, insomnia, anxiety, cardiovascular disease — and each brings its own prescription. Sleep apnoea, which blunts the respiratory drive that is the main defence against opioid overdose, is both more common and frequently undiagnosed in this age group, particularly in women who present atypically.

And many people in their fifties have been on the same long-term opioid script since the prescribing expansion of the 1990s and early 2000s — a period when opioids were issued with insufficient understanding of what a decade of continuous use would mean for the body.

The general practice dimension

RACGP polling of over 1,000 respondents found that 38% of GPs encounter alcohol and other drug issues in their patients daily, and a further 34% weekly. This is not an addiction-medicine problem that general practice refers away; it is an everyday clinical reality.

Dr Hester Wilson, Chair of the RACGP Specific Interests Addiction Medicine group, identified the central tension clearly: opioids are most commonly used to manage chronic pain, and the people who need them have not stopped needing them. A blunt policy response that removes access to pain relief is not clinically appropriate. But the current trajectory — a 15% year-on-year rise in unintentional overdose deaths — is also not acceptable.

The asks being made of government include longer funded consultation times for complex medication conversations, expanded access to naloxone, and better resourcing for structured medication reviews in general practice. These are not radical reforms; they are the clinical basics that the current funding model consistently undervalues.

---

2 cents

Two practical things for anyone reading this.

First: if you or someone close to you takes an opioid — even a prescribed one — alongside a benzodiazepine, a sleep medication, or alongside regular alcohol, that combination warrants a conversation with your GP or pharmacist. A Home Medicines Review is a Medicare-funded service that gives a pharmacist a structured look at everything being taken, including over-the-counter products, supplements, and alcohol patterns. Naloxone, the opioid reversal medication, is available without prescription at Australian pharmacies. If opioids are present in your household, knowing naloxone exists is worth knowing.

Second: if you have noticed a gradual increase in how much someone you care about takes — or what they take it with — and have chalked it up to their chronic pain management, the current data suggests that observation is worth acting on. Not with alarm, but with a direct, gentle conversation and possibly a GP appointment.

This is general health information and does not constitute individual clinical advice.

---

Verdict

Verdict: yes — worth knowing about.

Australia’s drug-induced deaths have reached a record high, with the 50–59 age group leading unintentional overdose fatalities for the first time. The driving substances are prescription opioids, benzodiazepines, and stimulants, frequently in combination. The data is new; the tools to address it — medicines reviews, naloxone, longer consultation funding — are available but underutilised. If any part of this picture is your picture, it is the right week to bring it to your GP.

---

Sources cited

1. Australia’s Annual Overdose Report Snapshot 2026 — Penington Institute
2. Drug-induced deaths reach record high — newsGP
3. The over-50s are most likely to overdose — The Conversation